Intravenous Artesunate and Malaria (IVAS)

University of Khartoum

Status and phase: Unknown; Phase 4

Conditions: Malaria

Treatments: Drug: Quinine; Drug: artesunate

Study type: Interventional

Funder types: Other

Identifiers

NCT01805232

artesunate and malaria

Details and patient eligibility

About

Intravenous artesunate is egual to quinine in the treatment of severe malaria

Full description

Intravenous artesunate is egual to quinine in the treatment of severe malaria in the form of fever clearance time and parasite clearance time

Enrollment: 80 estimated patients

Sex: All

Ages: 1 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

severe P.falciparum malaria-

Exclusion criteria

mixed infection Pregnant women -

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

80 participants in 2 patient groups

artesunate

Experimental group

Description:

intravenous artesunate 80 mg/kg initially then after 8 hours then daily

Treatment:

Drug: Quinine

Drug: artesunate

quinine

Active Comparator group

Description:

quinine infusion 80 mg/kg every 8 hours

Treatment:

Drug: Quinine

Drug: artesunate